



PRESS RELEASE • PRESS RELEASE • PRESS RELEASE

NEOVACS ANNOUNCES ITS PARTICIPATION IN UPCOMING INVESTOR CONFERENCES

Paris and Boston, October 28, 2015 – **NEOVACS (Alternext Paris: ALNEV)**, a leader in active immunotherapies for the treatment of autoimmune diseases, announced today its participation in several investor conferences during the fourth quarter 2015. Miguel Sieler, CEO of Neovacs, will present Neovacs' current development program and strategy at the following meetings:

BIO Europe 2015 Conference

Date: November 2-4, 2015 (conference on November 3 at 10:15 AM)

Location: Munich, Germany

Jefferies - 2015 Global Health Care Conference

Date: November 18, 2015

Location: London, United-Kingdom

Deutsches Eigenkapitalforum

Date: November 23-24, 2015 (conference on November 24 at 04:00 PM)

Location: Frankfurt, Germany

Neovacs will also be present at Actionaria, a conference dedicated to retail investors :

Salon Actionaria

Date: November 20-21, 2015

Location: Paris, France

As part of this exhibition, Miguel Sieler, CEO, will present at the "Agora des Présidents" on November 20 at 10:45 AM.

CEO Miguel Sieler commented, *"I am looking forward to introducing Neovacs to a new audience through our participation at these events. It is also a great opportunity for us to connect with current and prospective investors and update them on the progress that our Company is making toward advancing our lead immunotherapy candidate, IFN α -Kinoid."*

About Neovacs

Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFN α -Kinoid, an immunotherapy being developed for the indications of lupus and dermatomyositis. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.

For more information on Neovacs, please visit www.neovacs.fr

Contacts**NEOVACS**

Miguel Sieler - CEO

+33 (0)1 53 10 93 00

Investor Relations / Financial Communications – NewCap

Valentine Brouchet / Pierre Laurent

+33 (0)1 44 71 94 94

neovacs@newcap.fr

Investor Relations / Financial Communications Germany – MC Services

Raimund Gabriel

+49-89-21-02-28-30

raimund.gabriel@mc-services.eu

Press / U.S. Inquiries – The Ruth Group

Lee Roth

+1-646-536-70-23

lroth@theruthgroup.com